SU2C-SARC032: This Phase II trial is trying to determine whether using immunotherapy and radiotherapy for the treatment of localised, high-risk soft tissue sarcoma is more effective than giving radiotherapy aloneA Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

Summary

Participants will be randomised into an experimental or standard of care arm of the study. In the experimental arm, participants will receive neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. In this study, standard of care will include neoadjuvant radiotherapy followed by surgical resection. This trial is recruiting patients with undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic Liposarcoma of the extremity. Patients with non-melanomatous skin cancer, in situ carcinoma, or low-risk prostate cancer will also be considered for enrolment in this study.